Abstract
Oncogenic osteomalacia is a rare condition characterized by a low serum phosphate, reduced tubular reabsorption of phosphate and a low or inappropriately normal 1,25 dihydroxyvitamin D and is usually secondary to a phosphaturic mesenchymal tumor. Complete tumor resection results in resolution of all features. We report a patient with oncogenic osteomalacia and concurrent secondary hyperparathyroidism. Serum phosphate failed to normalize preoperatively with octreotide therapy, although this treatment did suppress serum FGF23. The postoperative course was distinguished by marked hyperphosphatemia that was associated with elevated serum 1,25 dihydroxyvitamin D concentrations.
MeSH terms
-
Aged
-
Antineoplastic Agents, Hormonal / therapeutic use*
-
Biomarkers / analysis
-
Biomarkers / blood
-
Bone and Bones / diagnostic imaging
-
Combined Modality Therapy
-
Female
-
Fibroblast Growth Factor-23
-
Fibroblast Growth Factors / analysis
-
Fibroblast Growth Factors / blood*
-
Humans
-
Hyperparathyroidism / drug therapy*
-
Hyperparathyroidism / etiology
-
Hyperparathyroidism / surgery
-
Octreotide / therapeutic use*
-
Osteomalacia / complications
-
Osteomalacia / drug therapy*
-
Osteomalacia / surgery
-
Phosphates / blood
-
Tomography, X-Ray Computed
-
Treatment Outcome
-
Vitamin D / analogs & derivatives
-
Vitamin D / blood
Substances
-
Antineoplastic Agents, Hormonal
-
Biomarkers
-
FGF23 protein, human
-
Phosphates
-
Vitamin D
-
Fibroblast Growth Factors
-
1,25-dihydroxyvitamin D
-
Fibroblast Growth Factor-23
-
Octreotide